P8A:SGX
Cordlife Group Ltd
0,12 SGD
0,00%
(0,00) 1 d
12 oct, 9:49:20 GMT+8 · SGD
search
Todos los símbolos
| Símbolo | Precio | Cambio | % de cambio |
|---|
insights_autoGenerando estadísticas principales de P8A...
Cap. burs.
32,37 M
Vol. medio
1,32 mil
Volumen
0,00
Máximo en 52 sem.
0,26 SGD
Mínimo en 52 sem.
0,10 SGD
BPA
-0,04 SGD
Acciones en circulación
267,53 M
N.º de empleados
111
Cap. burs.
32,37 M
Vol. medio
1,32 mil
Volumen
0,00
Máximo en 52 sem.
0,26 SGD
Mínimo en 52 sem.
0,10 SGD
BPA
-0,04 SGD
Acciones en circulación
267,53 M
N.º de empleados
111
Noticias
De fuentes web y partners de noticias
Yahoo Finanzas
·
hace 3 horas
Nasdaq pierde 4.5% semanal y Las tecnológicas arrastran al S&P 500
XTB.com
·
hace 6 horas
Resultados en Wall Street: ganadores y perdedores del S&P 500
El Ecosistema Startup
·
hace 4 horas
S&P 500 sube a 7.744 con rotación fuera de la IA
Cryptonews.net
·
hace 1 día
Grayscale afirma que 57% de las acciones del S&P 500 son más volátiles que Bitcoin
Perfil
Cordlife Group Limited, is a consumer health company incorporated in May 2001 and a provider of cord blood and cord lining banking services in Asia. Cordlife has been listed on the mainboard of SGX since March 2012.
Cordlife Group owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six markets including Singapore, Hong Kong, India, Indonesia, and the Philippines. Beyond cord blood and cord lining banking, Cordlife offers diagnostics services, particularly for the mother and child segment, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.
Cordlife's stem cell processing and storage facilities in Singapore, Hong Kong, India, Indonesia, the Philippines and Malaysia were accredited by AABB until 2024 when its accreditation was withdrawn.
In November 2023, the Ministry of Health of Singapore revealed that Cordlife Group had exposed cryopreserved cord blood units at suboptimal temperatures, damaging the cord blood units belonging to at least 2,150 clients and rendering them unsuitable for stem cell transplant purposes. Wikipedia
Acerca de Cordlife Group Ltd